First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers

Inappropriate and chronic activation of the cytosolic NOD‐, LRR‐, and pyrin domain‐containing 3 (NLRP3) inflammasome, a key component of innate immunity, likely underlies several inflammatory diseases, including coronary artery disease. This first‐in‐human phase I trial evaluated safety, pharmacokin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Fei, Kunder, Rebecca, Chu, Tom, Hains, Avis, Nguyen, Allen, McBride, Jacqueline M., Zhong, Yu, Santagostino, Sara, Wilson, Maria, Trenchak, Abigail, Chen, Liuxi, Ly, Justin, Moein, Anita, Lewin‐Koh, Nicholas, Raghavan, Vibha, Osaghae, Uyi, Wynne, Chris, Owen, Ryan, Place, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499406/
https://www.ncbi.nlm.nih.gov/pubmed/37350225
http://dx.doi.org/10.1111/cts.13576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499406/
https://www.ncbi.nlm.nih.gov/pubmed/37350225
http://dx.doi.org/10.1111/cts.13576

Ejemplares similares